At a glance

ClinicalIndex Comparison Record

N/ACompleted· 3 enrolled

Drug / intervention

Rescriptordrug

Likely dose

Rescriptor 200mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00823966

NCT00823966N/ACompleted

Compare CT.gov

Drug Use Investigation For Rescriptor (Regulatory Post Marketing Commitment Plan)

Pfizer·observational·Posted Jan 16, 2009·Updated Jul 5, 2010

In Brief

An observational study evaluating Rescriptor for HIV-1 Infection. Completed, enrolled 3 participants.

Detailed Summary

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Local Product Document (LPD) (unlisted adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Study Details

Study Typeobservational

Allocation--

Masking--

Primary Purpose--

ConditionsHIV-1 Infection

Countries--

Collaborators--

Timeline

N/ACompletedFinished

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartDec 2003

First PostedJan 2009

Primary CompletionMar 2009

TodayJul 2026

First PostedJan 16, 2009

Enrollment StartDec 1, 2003

Primary CompletionMar 1, 2009

TodayJul 2, 2026

Enrollment to primary: 5.3 yearsPosted 17.5 years ago

Interventions

Rescriptordrug

RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. "The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."